ReviewDose-response : a publication of International Hormesis Society
The LNT Model and ALARA in Diagnostic Imaging: A Critical Review of Scientific Evidence in the Low-Dose Range.
Review in Dose-response : a publication of International Hormesis Society. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The Linear No-Threshold (LNT) model and the As Low As Reasonably Achievable (ALARA) principle form the cornerstone of contemporary radiation protection. Although these frameworks were designed as conservative regulatory tools, their extrapolation to the low-dose and dose-rate (LDDR) range commonly encountered in diagnostic imaging remains scientifically contentious. Objective: This review critically examines the scientific basis for applying the LNT model and the ALARA principle in the LDDR range (1-50 mGy) routinely encountered in diagnostic imaging, with the aim of evaluating whether current regulatory practices are proportionate to demonstrated risks. Methods: We conducted a narrative review of peer-reviewed literature published between 1995 and 2025, retrieved from PubMed, Scopus, and Web of Science using the search terms "LNT model," "low-dose radiation," "ALARA," "radiation hormesis," "adaptive response," and "diagnostic reference levels." Priority was given to systematic reviews, large-cohort epidemiological studies, and consensus statements from professional organizations (ICRP, UNSCEAR, AAPM, HPS, IOMP). Studies were grouped thematically into radiobiological evidence, epidemiological evidence, and clinical/policy implications. We acknowledge that this is a non-systematic review and that selection bias cannot be excluded. Results: Multiple lines of radiobiological evidence-including DNA repair fidelity at low doses, adaptive cellular responses, apoptotic clearance of damaged cells, and immune surveillance-suggest that the dose-response relationship for stochastic effects in the LDDR range is unlikely to be linear. Large-scale epidemiological studies, including atomic bomb survivor reanalyses, occupational cohorts, and high-background radiation populations, generally fail to demonstrate statistically significant excess cancer risk below approximately 100 mGy, although confidence intervals remain wide. Case examples in scoliosis screening, mammography, and low-dose CT lung cancer screening illustrate scenarios in which overly conservative ALARA implementation may delay or deter clinically beneficial imaging. Conclusions: Within the LDDR range, the available evidence does not support a linear dose-response relationship, and the indiscriminate application of ALARA based on hypothetical risks may produce net harm through deferred imaging, radiophobia, and inefficient resource allocation. We propose that radiation protection in medical imaging shift toward an evidence-informed framework that prioritizes image quality optimization, individualized risk assessment, and the adoption of complementary principles such as ASARA (As Safe As Reasonably Achievable) and AHARA (As High As Reasonably Achievable benefits). A linear-with-threshold (LT) model and the adverse outcome pathway (AOP) framework warrant further investigation as alternatives to LNT for regulatory purposes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.